Back to top

immuno-therapy: Archive

Zacks Equity Research

Lilly (LLY) Hits Record High on Crohn's Disease Study Data

Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.

JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNPositive Net Change BMYPositive Net Change MRKPositive Net Change LGNDPositive Net Change

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXPositive Net Change UTHRPositive Net Change LGNDPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change AMGNPositive Net Change MRNANegative Net Change